340 related articles for article (PubMed ID: 15217925)
21. Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series.
Wolf J; Richardson PG; Schuster M; LeBlanc A; Walters IB; Battleman DS
Clin Adv Hematol Oncol; 2008 Oct; 6(10):755-60. PubMed ID: 18997666
[TBL] [Abstract][Full Text] [Related]
22. Bortezomib therapy following first relapse.
Orlowski RZ;
Oncology (Williston Park); 2005 Jan; 19(1):23-6. PubMed ID: 15743149
[No Abstract] [Full Text] [Related]
23. Bortezomib and extramedullary disease in multiple myeloma: the shine and dark side of the moon.
Ali R; Ozkalemkas F; Ozkan A; Ozkocaman V; Ozcelik T; Ozan U; Kurt M; Tunali A
Leuk Res; 2007 Aug; 31(8):1153-5. PubMed ID: 16945413
[No Abstract] [Full Text] [Related]
24. Molecule of the month. Bortezomib.
Drug News Perspect; 2003 Jun; 16(5):324. PubMed ID: 12942163
[No Abstract] [Full Text] [Related]
25. Bortezomib.
Paramore A; Frantz S
Nat Rev Drug Discov; 2003 Aug; 2(8):611-2. PubMed ID: 12908468
[No Abstract] [Full Text] [Related]
26. Concurrent radiation therapy and bortezomib in myeloma patient.
Berges O; Decaudin D; Servois V; Kirova YM
Radiother Oncol; 2008 Feb; 86(2):290-2. PubMed ID: 18199515
[No Abstract] [Full Text] [Related]
27. Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial.
Richardson PG; Barlogie B; Berenson J; Singhal S; Jagannath S; Irwin DH; Rajkumar SV; Srkalovic G; Alsina M; Anderson KC
Cancer; 2006 Mar; 106(6):1316-9. PubMed ID: 16470606
[TBL] [Abstract][Full Text] [Related]
28. Bortezomib, thalidomide, and dexamethasone for relapsed multiple myeloma: add it up and wait.
Badros A; Gahres N
Clin Adv Hematol Oncol; 2005 Dec; 3(12):916-7; discussion 918. PubMed ID: 16555432
[No Abstract] [Full Text] [Related]
29. Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma.
Zangari M; Guerrero J; Cavallo F; Prasad HK; Esseltine D; Fink L
Haematologica; 2008 Jun; 93(6):953-4. PubMed ID: 18515882
[No Abstract] [Full Text] [Related]
30. Bortezomib: new drug. A last resort in myeloma: modest efficacy, major risks.
Prescrire Int; 2005 Jun; 14(77):94-8. PubMed ID: 15981389
[TBL] [Abstract][Full Text] [Related]
31. Bortezomib: a novel therapy approved for multiple myeloma.
Richardson PG; Anderson KC
Clin Adv Hematol Oncol; 2003 Oct; 1(10):596-600. PubMed ID: 16258456
[TBL] [Abstract][Full Text] [Related]
32. Proteasome inhibition: a new approach for the treatment of malignancies.
Spano JP; Bay JO; Blay JY; Rixe O
Bull Cancer; 2005 Nov; 92(11):E61-6, 945-52. PubMed ID: 16316823
[TBL] [Abstract][Full Text] [Related]
33. Proteasome inhibitor holds promise for patients with refractory multiple myeloma.
Expert Rev Anticancer Ther; 2001 Dec; 1(4):509-10. PubMed ID: 12113081
[No Abstract] [Full Text] [Related]
34. Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma.
Jagannath S; Barlogie B; Berenson JR; Siegel DS; Irwin D; Richardson PG; Niesvizky R; Alexanian R; Limentani SA; Alsina M; Esseltine DL; Anderson KC
Br J Haematol; 2008 Nov; 143(4):537-40. PubMed ID: 18783399
[TBL] [Abstract][Full Text] [Related]
35. [Proteasome inhibitors].
Hatake K; Mishima Y; Terui Y
Gan To Kagaku Ryoho; 2004 Jul; 31(7):999-1002. PubMed ID: 15272575
[TBL] [Abstract][Full Text] [Related]
36. Bortezomib retreatment in relapsed multiple myeloma - results from a retrospective multicentre survey in Germany and Switzerland.
Hrusovsky I; Emmerich B; von Rohr A; Voegeli J; Taverna C; Olie RA; Pliskat H; Frohn C; Hess G
Oncology; 2010; 79(3-4):247-54. PubMed ID: 21372599
[TBL] [Abstract][Full Text] [Related]
37. Use of intrapleural bortezomib in myelomatous pleural effusion.
Iannitto E; Minardi V; Tripodo C
Br J Haematol; 2007 Nov; 139(4):621-2. PubMed ID: 17979947
[No Abstract] [Full Text] [Related]
38. Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma.
Richardson PG; Mitsiades C; Ghobrial I; Anderson K
Curr Opin Oncol; 2006 Nov; 18(6):598-608. PubMed ID: 16988581
[TBL] [Abstract][Full Text] [Related]
39. Bortezomib-based therapy as induction regimen of an autograft program in front-line treatment of multiple myeloma with end-stage renal disease.
Siniscalchi A; Dentamaro T; Perrotti A; Tatangelo P; de Fabritiis P; Caravita T
Ann Hematol; 2010 Aug; 89(8):821-2. PubMed ID: 19953253
[No Abstract] [Full Text] [Related]
40. The proteasome--an emerging therapeutic target in cancer.
Mitchell BS
N Engl J Med; 2003 Jun; 348(26):2597-8. PubMed ID: 12826633
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]